公开(公告)号：US11535677B2

公开(公告)日：2022-12-27

申请号：US16303587

申请日：2017-08-10

申请人： Legend Biotech USA Inc.

发明人： Xiaohu Fan ,  Qiuchuan Zhuang ,  Pingyan Wang ,  Lin Wang ,  Lei Yang ,  Jiaying Hao ,  Dan Zhao ,  Xian He

IPC分类号： C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C07K16/30 ,  A61K35/17 ,  C12N5/0783 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63

摘要： Provided herein are single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) having the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

公开(公告)号：US10934363B2

公开(公告)日：2021-03-02

申请号：US15751609

申请日：2016-08-10

申请人： Legend Biotech USA Inc.

发明人： Xiaohu Fan ,  Chuan-Chu Chou ,  Qiuchuan Zhuang ,  Pingyan Wang ,  Lin Wang ,  Lei Yang ,  Jiaying Hao

IPC分类号： C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C07K16/30 ,  A61K35/17 ,  C12N5/0783 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63

摘要： The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

公开(公告)号：US11186647B2

公开(公告)日：2021-11-30

申请号：US17168100

申请日：2021-02-04

申请人： Legend Biotech USA Inc.

发明人： Xiaohu Fan ,  Qiuchuan Zhuang ,  Pingyan Wang ,  Lin Wang ,  Lei Yang ,  Jiaying Hao

IPC分类号： C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C07K16/30 ,  A61K35/17 ,  C12N5/0783 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63

摘要： The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.